Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1681/ASN.2011121186

http://scihub22266oqcxt.onion/10.1681/ASN.2011121186
suck pdf from google scholar
22677550!3380652!22677550
unlimited free pdf from europmc22677550    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22677550&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid22677550      J+Am+Soc+Nephrol 2012 ; 23 (7): 1229-37
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Pathology after eculizumab in dense deposit disease and C3 GN #MMPMID22677550
  • Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
  • J Am Soc Nephrol 2012[Jul]; 23 (7): 1229-37 PMID22677550show ga
  • Eculizumab might benefit C3 glomerulopathies mediated by dysregulation of the alternative complement pathway. Here, we report renal biopsy findings before and after eculizumab therapy in three patients with dense deposit disease and two with C3 GN. All pretreatment biopsies had glomerular and tubular basement membrane deposits that stained exclusively for C3 without significant Ig. After 1 year of therapy, there was reduction in active glomerular proliferation and neutrophil infiltration in three of five patients, consistent with effective C5 blockade, which prevents production of chemotactin C5a. One individual with mild mesangial disease had no significant change in activity or chronicity. One patient exhibited persistent activity and worsening chronicity despite therapy. Immunofluorescence showed no significant reduction in C3 or C5b-9, and electron microscopy revealed persistent deposits in all cases, suggesting a long t(1/2) of C5b-9 in extracellular matrix. Normal renal biopsies stained positive for C5b-9 in glomeruli, tubular basement membranes, and vessel walls, albeit at lower intensity than in C3 glomerulopathy. This indication of physiologic levels of C5b-9 activation in normal kidney potentially explains the localization of deposits in patients with dysregulation of the alternative complement pathway. All post-treatment biopsies showed de novo monoclonal staining for IgG-kappa in the same distribution as C3 and C5b-9, mimicking monoclonal Ig deposition disease (MIDD). Staining of the gamma heavy chain was restricted to the IgG2 and IgG4 subclasses, suggesting the binding of monoclonal eculizumab to C5 in renal tissues. The long-term effects of this apparent drug-tissue interaction are unknown.
  • |Adult[MESH]
  • |Antibodies, Monoclonal, Humanized/adverse effects/pharmacology/*therapeutic use[MESH]
  • |Biopsy[MESH]
  • |Cell Proliferation/drug effects[MESH]
  • |Complement C3/*metabolism[MESH]
  • |Complement C5a/metabolism[MESH]
  • |Complement Membrane Attack Complex/metabolism[MESH]
  • |Dose-Response Relationship, Drug[MESH]
  • |Glomerulonephritis, Membranoproliferative/*drug therapy/metabolism/*pathology[MESH]
  • |Glomerulonephritis/*drug therapy/metabolism/*pathology[MESH]
  • |Humans[MESH]
  • |Injections, Intravenous[MESH]
  • |Kidney Glomerulus/drug effects/metabolism/pathology[MESH]
  • |Male[MESH]
  • |Neutrophils/pathology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box